Amgen Ventures
Amgen Ventures is the corporate venture capital arm of Amgen that makes direct investments in early through late-stage biotechnology companies. It focuses on discovering and developing human therapeutics across oncology, inflammation, bone health, nephrology, metabolic disorders, neuroscience, and cardiovascular diseases, including in oncology areas such as signal transduction, cell cycle, and apoptosis, and in supportive care like mucositis and cachexia. In nephrology it targets renal failure and hyperparathyroidism; in inflammation, rheumatoid arthritis, psoriasis, lupus, inflammatory bowel disease, multiple sclerosis, asthma, COPD, and osteoarthritis; in cardiovascular disease, acute coronary syndromes, dyslipidemia, and heart failure; and in metabolic disorders, diabetes and osteoporosis. It also covers neuroscience areas like pain, Alzheimer's, Parkinson's, sleep, cognition, and schizophrenia. The firm engages in early-stage research collaborations and technology, including antibody platforms, biomarkers, and computational tools. Headquartered in Thousand Oaks, with offices in San Francisco, Seattle, and Cambridge, it typically invests 2-3 million per transaction, up to 10 million per company, and seeks ownership under 15 percent. Founded 2004.
https://crunchbase.com/organization/***
https://linkedin.com/company/***
https://signal.nfx.com/firms/***
146 past transactions
EnClear Therapies
Venture Round in 2024
EnClear Therapies develops device-based therapies for treating neurodegenerative diseases by removing toxic proteins from cerebrospinal fluid. Its initial targets are Amyotrophic Lateral Sclerosis (ALS) and Progressive Supranuclear Palsy (PSP). Incorporated in 2018, the company is based in Newburyport, Massachusetts.
Mindset Medical
Series A in 2024
Mindset Medical is a Health Care Company that develops a platform for clinical information. Through their platform physicians will understand patient pain, saves time for providers and patients, they eliminate paper and redundant forms, and allows providers more time for patients.
Mindset Medical was founded in 2016 in Phoenix, Arizona.
Enlaza Therapeutics
Series A in 2024
Founded in 2020, Enlaza Therapeutics is a biotechnology company based in La Jolla, California. It specializes in developing covalent protein therapeutics using a novel synthetic biology platform, aiming to deliver efficacious and safer treatments with prolonged effects and minimal systemic exposure.
Quantinuum
Corporate Round in 2024
Quantinuum is a global leader in quantum computing, dedicated to advancing quantum hardware and software solutions. With nearly 500 professionals, including over 370 scientists and engineers, the company focuses on materials discovery, cybersecurity, and next-generation quantum AI.
Culmination Bio
Series A in 2023
Culmination Bio is a startup that is developing a disease-independent patient data intelligence platform.
Generate Biomedicines
Series C in 2023
Generate Biomedicines, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapeutics through its pioneering platform in Generative Biology. Established in 2018, the company utilizes machine learning to analyze existing proteins, enabling it to understand the principles governing the relationship between genetic sequences and protein structure. This approach facilitates the invention of novel antibodies, peptides, enzymes, receptors, and other protein-based therapeutics optimized for specific biological functions. By harnessing its advanced technology, Generate Biomedicines aims to accelerate drug discovery by generating new biological molecules with significant therapeutic potential. Originally known as Generate Biologics, the company adopted its current name in March 2020 to reflect its expanded focus on biomedicine.
Feldan Therapeutics
Series B in 2023
Feldan Therapeutics specializes in intracellular drug delivery using its patented Feldan Shuttle technology. This platform enables rapid, safe, and efficient transport of therapeutic agents into cells, with a focus on developing treatments for serious diseases such as skin and lung conditions.
Horizon Pharma
Acquisition in 2022
Horizon Therapeutics is a biopharmaceutical company based in Northbrook, Illinois, established in 2005. The company specializes in developing prescription drugs aimed at providing relief for mild to moderate pain and managing arthritis. Among its notable product candidates are HZT-501, a proprietary fixed-dose combination of a nonsteroidal anti-inflammatory drug (NSAID) and ibuprofen, and HZT-602, which is a combination oral medication that includes naproxen and famotidine.
Casma Therapeutics
Series C in 2022
Casma Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, that specializes in developing innovative therapeutic strategies centered on the natural cellular process of autophagy. Founded in 2017, the company aims to enhance autophagy to improve the clearance of unwanted proteins, organelles, and pathogens, thereby addressing significant medical challenges. Casma Therapeutics is advancing preclinical programs targeting various conditions, including muscle disorders, liver disease, inflammatory disorders, and neurodegenerative diseases. By harnessing and manipulating the autophagy system, the company seeks to arrest or reverse disease progression, ultimately enabling physicians to meet unmet medical needs and provide effective treatments for patients with serious health issues.
Inversago Pharma
Series C in 2022
Inversago Pharma Inc. is a preclinical-stage biotechnology company based in Montreal, Canada, specializing in the development of peripherally-restricted CB1 receptor inverse agonists aimed at treating various metabolic and fibrotic disorders. Founded in 2015, the company focuses on creating innovative therapies for conditions such as Prader-Willi syndrome, diabetes, and complications related to obesity. Its pipeline includes treatments for diabetic kidney disease, non-alcoholic steatohepatitis, and progressive fibrosis, including interstitial lung disease. Inversago Pharma aims to improve patient outcomes by offering new therapeutic options that target the underlying mechanisms of these diseases.
Neumora Therapeutics
Series B in 2022
Neumora Therapeutics is a clinical-stage biotechnology company focused on developing precision medicines for brain diseases by combining data science with neuroscience. Founded to address the global brain disease crisis, Neumora takes an innovative approach to treatment development. The company has established a robust therapeutic pipeline that includes seven clinical and preclinical neuroscience programs targeting novel mechanisms of action for various underserved neuropsychiatric and neurodegenerative disorders. Neumora plans to advance its pipeline further by initiating multiple clinical trials across its programs in the upcoming 12 to 18 months.
ImmunoScape
Venture Round in 2022
ImmunoScape develops immune profiling systems and analytical tools to support immunotherapy clinical development. Its Deep Immunomics platform integrates mass cytometry, single-cell sequencing, and proprietary computational analytics to profile immune cells with high resolution and to identify antigen-specific T cells, delivering an online data analysis pipeline. The platform provides reproducible immune profiling information used to understand safety and efficacy of immunotherapies and to identify drug targets across oncology and infectious diseases, applicable throughout research, development, and clinical testing.
ChemoCentryx
Acquisition in 2022
ChemoCentryx is a biopharmaceutical company developing new medications for inflammatory disorders, autoimmune diseases, and cancer. It focuses on orally-administered small molecule therapeutics targeting chemokine receptors.
BigHat Biosciences
Series B in 2022
BigHat Biosciences is a biotechnology company that develops an AI-guided platform for designing and characterizing antibodies and other therapeutic proteins. The platform combines a wet laboratory with artificial intelligence and machine learning to enable antibody discovery and optimization, helping drug developers create antibodies and novel biotherapeutic designs. It emphasizes multi-objective, data-driven workflows to improve safety, biophysical properties, and efficacy of antibody candidates. Founded in 2019 and based in San Carlos, California.
Kernal Biologics
Series A in 2022
Kernal Biologics, Inc. is a biotechnology company focused on designing and developing mRNA immunotherapies aimed at treating diseases such as COVID-19 and various cancers. Founded in 2016 and headquartered in Cambridge, Massachusetts, the company leverages its mRNA platform to enable researchers and organizations to create vaccines and therapeutics. Kernal’s innovative approach allows specific cells to produce their own therapeutic agents. With a team that has strong connections to prestigious institutions like MIT and Harvard, as well as experience in the pharmaceutical industry, Kernal Biologics has garnered recognition for its work, winning multiple awards from notable organizations, including Amgen and NASA.
ReCode Therapeutics
Series B in 2022
ReCode Therapeutics, Inc. is a biopharmaceutical company focused on developing precision medicines for pulmonary diseases, particularly targeting genetic conditions such as primary ciliary dyskinesia and cystic fibrosis. Founded in 2015 and based in Menlo Park, California, the company utilizes a groundbreaking selective organ targeting (SORT) lipid nanoparticle platform. This innovative technology facilitates the precise delivery of genetic therapies, including mRNA and gene correction therapeutics, to specific organs and cells beyond the liver. By overcoming limitations of traditional gene therapy approaches, ReCode Therapeutics aims to address the needs of patients with rare and life-limiting respiratory diseases, thus providing new treatment options for those affected by genetic disorders.
Senti Biosciences
Post in 2022
Senti Biosciences is a biotechnology company focused on synthetic biology. It develops gene circuit platforms to engineer therapeutics, with a focus on improving precision and control in cancer treatments.
Code Biotherapeutics
Series A in 2022
Code Biotherapeutics is a next-generation gene therapy company pioneering the development of targeted non-viral gene therapies to treat serious and life-threatening genetic diseases. Code Bio leverages its novel multivalent synthetic DNA delivery platform, 3DNA, which has been engineered to overcome many of the challenges inherent with viral-based gene therapies such as immunogenicity, size and delivery limitations, re-dosability, and manufacturing complexity. The company is advancing an internal pipeline focused on select rare disease programs as well as establishing partnerships to take forward programs in both rare and prevalent diseases.
Olive Diagnostics
Seed Round in 2022
Olive Diagnostics is a company that has developed an innovative passive urine analysis sensor designed to enhance early disease detection and chronic disease management. This sensor, which can be easily mounted to any toilet, utilizes spectroscopy combined with artificial intelligence-based analytics to monitor the urine stream. By continuously collecting and analyzing health data, the device provides users with real-time health alerts that promote awareness of their bodily functions. The technology not only supports individual health management but also offers valuable insights for pharmaceutical and contract research organizations to track drug compliance and usage. With its focus on proactive health monitoring, Olive Diagnostics aims to make urine lab services accessible even in nonindustrial nations, thereby transforming personal health care through advanced, continuous biomarker tracking.
TileDB
Venture Round in 2022
TileDB, Inc. is a technology company specializing in the management of multi-dimensional array data, primarily for scientific applications. Founded in 2017 and headquartered in Cambridge, Massachusetts, with an additional location in Athens, Greece, TileDB offers a cloud-based storage platform and embedded storage engine. Its innovative software is designed to handle diverse data types, including unstructured and multimodal data, making it suitable for complex scientific inquiries such as genomic research and biomedical imaging. TileDB enables users to access, analyze, and share intricate datasets effectively, supporting scientific teams in pharmaceutical and biotechnology sectors to advance drug discovery and other research initiatives. Through its robust platform, TileDB facilitates parallel data analytics and integrates various dimensions and attributes within data arrays, positioning itself as a critical tool for scientific breakthroughs.
Celsius Therapeutics
Series B in 2022
Celsius Therapeutics, Inc. is a biotechnology company focused on developing precision medicines for patients suffering from cancer and autoimmune diseases. Founded in 2018 and based in Cambridge, Massachusetts, the company employs a multidisciplinary approach, integrating the expertise of scientists, computational biologists, and clinicians. Celsius Therapeutics utilizes advanced techniques such as single-cell genomic analysis and machine learning to identify and develop innovative therapeutic solutions. By leveraging these cutting-edge technologies, the company aims to create life-changing medicines that address unmet medical needs.
CancerIQ
Series B in 2022
CancerIQ is a precision health technology company focused on empowering healthcare providers to identify and manage patients at high risk for cancer. Its platform offers a comprehensive suite of tools, including predictive analytics and screening resources, to help clinicians accurately stratify patient risk and guide them toward appropriate genetic testing, screening, or treatment options. The platform features a robust content library of evidence-based guidelines and risk models, facilitating informed decision-making. Additionally, CancerIQ provides digital tools for genetic test ordering and patient management, aimed at enhancing patient education and engagement. By streamlining these processes, the company enables healthcare providers to improve patient outcomes and reduce the overall cost of care through early cancer detection.
Accure Health
Non Equity Assistance in 2022
Accure Health is a privately held precision medicine company that develops AI-powered solutions to tailor therapies to individual patients based on biomarker profiles. The company aims to deliver targeted treatments to the right cells by combining proprietary protein design pipelines with a patented biomarker device, enabling biomarker-guided care and precision therapies.
Gandeeva Therapeutics
Series A in 2022
Gandeeva Therapeutics is a precision biotechnology company that combines cryogenic electron microscopy (cryo-EM) and machine learning to discover and develop therapeutics by targeting and modulating key protein-protein interactions. Its structure-guided drug discovery platform comprises SPOTLIGHT for target prediction and validation, HYPERFOCUS for hit identification from virtual and fragment libraries, and CRYO-CADD for lead optimization. The company pursues a preclinical oncology program focused on difficult-to-treat cancers with novel protein interaction modulators, including interfacial glues and allosteric inhibitors. Headquartered in the Greater Vancouver area of Canada, Gandeeva aims to advance differentiated therapeutics and improve outcomes for patients by leveraging its integrated imaging, modeling, and screening capabilities.
Neumora Therapeutics
Corporate Round in 2021
Neumora Therapeutics is a clinical-stage biotechnology company focused on developing precision medicines for brain diseases by combining data science with neuroscience. Founded to address the global brain disease crisis, Neumora takes an innovative approach to treatment development. The company has established a robust therapeutic pipeline that includes seven clinical and preclinical neuroscience programs targeting novel mechanisms of action for various underserved neuropsychiatric and neurodegenerative disorders. Neumora plans to advance its pipeline further by initiating multiple clinical trials across its programs in the upcoming 12 to 18 months.
TeneoBio
Acquisition in 2021
TeneoBio, Inc. is a biotechnology company based in Menlo Park, California, specializing in the development of human heavy chain antibodies, known as UniAbs, for therapeutic applications. Founded in 2009, the company focuses on creating biologics to treat various conditions, including cancer, autoimmune diseases, and infectious diseases. TeneoBio has a pipeline of products in both pre-clinical and clinical stages, targeting ailments such as multiple myeloma, prostate cancer, and immune disorders. The company employs a proprietary antibody discovery platform that utilizes genetically engineered animals, next-generation sequencing, and advanced bioinformatics to identify unique binding molecules tailored for specific therapeutic targets. This innovative approach aims to enhance the immune response in patients and address significant health challenges.
GPB Scientific
Venture Round in 2021
GPB Scientific, LLC is a biotechnology company specializing in the development of a liquid biopsy platform designed to isolate rare circulating tumor cells from a patient's blood while preserving their viability. The company offers a desktop fluidic system that processes whole blood through a disposable microchip, effectively separating red blood cells and normal white blood cells to yield a population of rare tumor cells. Founded in 2002 and based in Richmond, Virginia, GPB Scientific markets its innovative technology to life sciences companies and research institutions, boasting a robust portfolio of patents and expertise in microchip technology for size-based enrichment and affinity-based cell capture.
Rodeo Therapeutics
Acquisition in 2021
Rodeo Therapeutics Corp. is a Seattle-based drug development company that focuses on creating novel small molecule therapies aimed at tissue repair and regeneration. Founded in 2017, the company targets specific biological pathways and enzyme mechanisms critical for healing. Its primary objectives include developing treatments for inflammatory bowel disease and enhancing blood cell reconstitution after bone marrow transplants. Rodeo's innovative approach involves increasing tissue levels of prostaglandin PGE2 by inhibiting the enzyme 15-PGDH, which has shown promise in protecting against colitis and promoting liver regeneration in various animal models. This research positions Rodeo Therapeutics to contribute significantly to the medical management of these conditions.
Five Prime Therapeutics
Acquisition in 2021
Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company specializing in the discovery and development of innovative protein therapeutics. Headquartered in South San Francisco, California, the company employs its proprietary ProScreen Engine to systematically screen relevant proteins in the human body, facilitating the identification of optimal treatments for various clinical indications. Five Prime's key product candidates include Bemarituzumab, an antibody targeting fibroblast growth factor receptor 2b, currently in Phase 3 clinical trials for gastric cancer, and FPA150, a CD8 T cell checkpoint inhibitor in Phase 1a/1b trials for multiple cancers. Other notable candidates are FPT155, a soluble CD80 fusion protein enhancing T cell co-stimulation, and Cabiralizumab, which inhibits the colony stimulating factor-1 receptor in combination with Opdivo for cancer treatment. Additionally, Five Prime has active collaborations with several prominent pharmaceutical companies, enhancing its research and development capabilities. Founded in 2001, Five Prime Therapeutics is committed to advancing novel therapies to address challenging medical needs.
Senti Biosciences
Series B in 2021
Senti Biosciences is a biotechnology company focused on synthetic biology. It develops gene circuit platforms to engineer therapeutics, with a focus on improving precision and control in cancer treatments.
NoviSci
Seed Round in 2021
NoviSci is a software analytics and services company focused on enhancing population health outcomes, particularly for vulnerable patients with complex health conditions. The company leverages advanced data science techniques to visualize and analyze health data, employing modern epidemiological methods grounded in sound scientific principles. Through its innovative tools, NoviSci aims to improve the health and well-being of individuals by providing insights that drive better decision-making in healthcare settings.
DJS Antibodies
Venture Round in 2020
DJS Antibodies Ltd is a biotechnology company based in Bicester, United Kingdom, established in 2014. The company focuses on the design and discovery of novel therapeutic monoclonal antibodies specifically targeting G-protein-coupled receptors (GPCRs). DJS Antibodies aims to develop innovative therapeutics for chronic inflammatory diseases by utilizing its advanced technology to create first-in-class antibody therapeutics for previously challenging disease targets. By specializing in the research and discovery of functional antibodies against complex protein targets that have eluded traditional drug discovery efforts, DJS Antibodies endeavors to provide effective treatments for diseases that are currently considered undruggable and untreatable.
Carmot Therapeutics
Series C in 2020
Carmot Therapeutics, Inc. is a clinical-stage biotechnology company based in Berkeley, California, with an additional office in San Francisco. Founded in 2008, it focuses on discovering and developing innovative therapies for patients with metabolic diseases, including obesity and diabetes. Utilizing its proprietary Chemotype Evolution technology, Carmot Therapeutics aims to address the underlying causes of these conditions and accelerate the discovery of effective treatments. The company’s portfolio includes several clinical-stage drug candidates, such as CT-388 and CT-996, which are designed as GLP-1 receptor agonists for the treatment of obesity and type 2 diabetes, and CT-868, intended for type 1 diabetes patients who are overweight or obese. Through these efforts, Carmot Therapeutics seeks to create life-changing therapeutics that improve the health outcomes of individuals affected by metabolic diseases.
Science 37
Venture Round in 2020
Science 37 specializes in decentralized clinical trials, offering a technology-driven approach that enables patients to participate from their homes. The company's platform connects researchers with patients via telemedicine investigators and mobile nurses, accelerating trial enrollment and retention while reaching a more diverse patient population.
BeiGene
Post in 2020
Founded in 2010, BeiGene is a global biotechnology company dedicated to discovering and developing innovative oncology treatments. With over 9,200 employees worldwide, the company aims to make its therapies accessible and affordable to cancer patients globally. Its flagship product, BRUKINSA® (zanubrutinib), has been approved in over 65 markets for various blood cancers.
Syapse
Series F in 2020
Syapse, Inc. is a technology company that specializes in precision medicine through its innovative software platform, which aggregates and analyzes clinical, molecular, treatment, and outcomes data. Founded in 2008 and headquartered in San Francisco, California, with an additional office in Radnor, Pennsylvania, Syapse aims to enhance healthcare by providing actionable insights that support data-driven decision-making in precision oncology. The company operates the Syapse Learning Health Network, a global network that enables health systems and life sciences collaborators to share real-world cancer data. This network empowers healthcare organizations to collaborate effectively, ensuring that oncologists and decision-makers have access to comprehensive patient insights at the point of care, ultimately driving improved outcomes for cancer patients. Syapse has established strategic partnerships, including a collaboration with Pfizer, to further its mission of delivering personalized care based on robust real-world evidence.
QurAlis Corporation
Series A in 2020
QurAlis Corporation is a Cambridge, Massachusetts-based clinical-stage biotechnology company developing precision therapeutics for amyotrophic lateral sclerosis and other neurodegenerative diseases. It focuses on drugs that directly target disease-causing genetic alterations using proprietary platforms and biomarkers to identify and treat patients with specific genetic mutations, aiming to halt disease progression and improve outcomes.
GPB Scientific
Venture Round in 2020
GPB Scientific, LLC is a biotechnology company specializing in the development of a liquid biopsy platform designed to isolate rare circulating tumor cells from a patient's blood while preserving their viability. The company offers a desktop fluidic system that processes whole blood through a disposable microchip, effectively separating red blood cells and normal white blood cells to yield a population of rare tumor cells. Founded in 2002 and based in Richmond, Virginia, GPB Scientific markets its innovative technology to life sciences companies and research institutions, boasting a robust portfolio of patents and expertise in microchip technology for size-based enrichment and affinity-based cell capture.
EnClear Therapies
Series A in 2020
EnClear Therapies develops device-based therapies for treating neurodegenerative diseases by removing toxic proteins from cerebrospinal fluid. Its initial targets are Amyotrophic Lateral Sclerosis (ALS) and Progressive Supranuclear Palsy (PSP). Incorporated in 2018, the company is based in Newburyport, Massachusetts.
Keck Graduate Institute
Grant in 2019
Keck Graduate Institute (KGI) is part of the prestigious Keck is one of the few graduate schools exclusively dedicated to the study of biosciences. The school’s graduate programs blend academics with business-oriented approaches to the field.
Otezla
Acquisition in 2019
Otezla® is a prescription medicine approved for the treatment of patients with moderate
BeiGene
Post in 2019
Founded in 2010, BeiGene is a global biotechnology company dedicated to discovering and developing innovative oncology treatments. With over 9,200 employees worldwide, the company aims to make its therapies accessible and affordable to cancer patients globally. Its flagship product, BRUKINSA® (zanubrutinib), has been approved in over 65 markets for various blood cancers.
Nkarta Therapeutics
Series B in 2019
Nkarta Therapeutics is a clinical-stage biopharmaceutical company focused on developing allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The company aims to harness the inherent power of NK cells to target and destroy tumor cells, offering a potent and better-tolerated alternative to traditional T-cell therapies for a broad range of cancer indications.
Aitia
Series D in 2019
Aitia is a leader in the application of Causal AI and Digital Twins focused on advancing drug discovery and development. The company utilizes machine learning and the convergence of multi-omic patient data to create Digital Twins that replicate the biological mechanisms of diseases. This innovative approach is particularly impactful in areas such as oncology, neurodegenerative disorders, and immunology. Aitia's Gemini Digital Twins are currently employed to identify novel therapies and expedite research and development in various conditions, including multiple myeloma, prostate cancer, Alzheimer’s Disease, Parkinson’s Disease, and Huntington’s Disease, with additional projects underway. The company collaborates with several prominent pharmaceutical firms, academic institutions, medical societies, and patient advocacy groups worldwide, thereby enhancing the potential for breakthroughs in medicine.
Nuevolution
Acquisition in 2019
Nuevolution is a prominent small molecule lead discovery company established in 2001 and headquartered in Copenhagen, Denmark. The firm specializes in developing innovative treatments for human diseases, particularly in oncology and inflammatory conditions. Central to its operations is Chemetics®, a proprietary drug discovery platform that combines wet chemistry with molecular biology, allowing for the rapid synthesis and DNA-tagging of millions of diverse small molecule compounds. This advanced technology enables efficient screening to identify potent drug leads at an unprecedented scale and speed. With a library exceeding 1 billion compounds, Nuevolution collaborates with various pharmaceutical and biotechnology companies, including notable partnerships with leading industry names. Additionally, the company is involved in a joint venture focused on the discovery and development of small molecule drugs targeting epigenetic factors. Nuevolution's capabilities have led to the identification of novel ligands with potential applications in addressing significant unmet medical needs across various therapeutic areas. The company is privately owned by a group of key Scandinavian investors.
NAVAN Technologies
Seed Round in 2019
NAVAN Technologies, Inc. is a pre-clinical stage biotechnology company based in South San Francisco, California, founded in 2016. The company specializes in developing and commercializing its proprietary NanoStraw platform technology, which provides a direct and gentle means of accessing the cytosol of cells. This innovative platform addresses a significant challenge in the field of cell and gene therapies by enabling the efficient delivery of various cargoes into difficult-to-transfect cells without causing disruption. NAVAN's technology aims to enhance the capabilities of researchers and improve the effectiveness of therapeutic applications in biotechnology.
Imago BioSciences
Series B in 2019
Imago BioSciences, Inc. is a clinical-stage biotechnology company based in Redwood City, California, founded in 2012. The company specializes in developing novel small molecule therapeutics aimed at treating hematologic diseases, including myelodysplastic syndromes, acute myelogenous leukemia, and other conditions associated with bone marrow failure. Central to its research is the enzyme lysine-specific demethylase 1 (LSD1), which is involved in the regulation of blood cell production. Imago BioSciences is focused on translating advanced scientific insights into transformative therapies that can alter the course of disease, thereby enhancing the quality and longevity of life for patients. Its lead product candidate, Bomedemstat, is an orally administered LSD1 inhibitor currently under evaluation for its potential to modify disease progression in patients with myeloproliferative neoplasms, a group of chronic bone marrow cancers.
Aetion
Series B in 2019
Aetion is a New York‑based company that builds a real‑world evidence platform. It aggregates claims, electronic health records, registries and clinical trial data to generate analytics that help payers, providers, biopharma and medical device firms assess the effectiveness and value of treatments. The platform’s rapid‑cycle analytics enable real‑time collaboration between payers, providers and life‑science companies, supporting value‑based care decisions. Founded in 2012 by Harvard Medical School faculty and data scientists, it has partnerships with McKesson and receives backing from major venture investors. The platform is used worldwide by health‑economists, epidemiologists and biostatisticians for database analytics and comparative‑effectiveness research.
Caraway Therapeutics
Series A in 2018
Caraway Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, that focuses on developing innovative treatments for neurodegenerative diseases by modulating mitophagy and autophagy. The company aims to address the degradation of toxic cellular components, which is a key factor in various neurodegenerative conditions, including Parkinson's disease and amyotrophic lateral sclerosis. By leveraging an understanding of critical neural pathways, Caraway Therapeutics seeks to discover and develop novel small molecules that can restore cellular balance and improve lysosomal function. Founded in 2018 and initially known as Rheostat Therapeutics, Inc., the company rebranded in 2019 to reflect its commitment to finding effective therapies for patients affected by these debilitating diseases.
QurAlis Corporation
Seed Round in 2018
QurAlis Corporation is a Cambridge, Massachusetts-based clinical-stage biotechnology company developing precision therapeutics for amyotrophic lateral sclerosis and other neurodegenerative diseases. It focuses on drugs that directly target disease-causing genetic alterations using proprietary platforms and biomarkers to identify and treat patients with specific genetic mutations, aiming to halt disease progression and improve outcomes.
Kymera Therapeutics
Series B in 2018
Kymera Therapeutics is a biotechnology company focused on targeted protein degradation. It employs a proprietary predictive modeling platform to discover novel small molecule therapeutics that selectively degrade disease-causing proteins.
Ribometrix
Series A in 2018
Ribometrix is a biotechnology company that develops platform therapeutics to discover and advance small molecule drugs that target functional three-dimensional RNA structures to treat human diseases. Founded in 2014 and based in Durham, North Carolina, it focuses on leveraging RNA structure analysis and proprietary tools, along with artificial intelligence, to identify compounds that modulate RNA biology and reduce disease-associated protein production.
Oxford Nanopore Technologies
Venture Round in 2018
Oxford Nanopore Technologies Limited is a biotechnology company specializing in the development and commercialization of nanopore-based sequencing technology for the analysis of DNA, RNA, proteins, and small molecules. Its innovative product lineup includes the portable MinION device, the benchtop PromethION, and the GridION system, all of which enable real-time data streaming and scalable sequencing for a variety of applications in scientific research, personalized medicine, environmental monitoring, and agriculture. The Flongle offers smaller, on-demand sequencing solutions, catering to users requiring rapid insights. Operating in over 80 countries, Oxford Nanopore's technology is designed for accessibility and ease of use, featuring straightforward library preparation and automated solutions. The company maintains a robust patent portfolio, supporting its ongoing research and development in both biological and solid-state nanopore technologies. Founded in 2005 and based in Oxford, United Kingdom, Oxford Nanopore Technologies also has offices in multiple countries, including the United States, China, and Germany.
Akili Interactive
Series C in 2018
Akili Interactive Labs, Inc., established in 2011 and headquartered in Boston, Massachusetts, specializes in developing digital medicine solutions. The company's core business involves creating video game-based technology to assess and enhance cognitive abilities. Akili's broad pipeline focuses on treating cognitive deficiencies and improving symptoms associated with various medical conditions, such as ADHD, MDD, ASD, and inflammatory diseases.
Aetion
Series B in 2018
Aetion is a New York‑based company that builds a real‑world evidence platform. It aggregates claims, electronic health records, registries and clinical trial data to generate analytics that help payers, providers, biopharma and medical device firms assess the effectiveness and value of treatments. The platform’s rapid‑cycle analytics enable real‑time collaboration between payers, providers and life‑science companies, supporting value‑based care decisions. Founded in 2012 by Harvard Medical School faculty and data scientists, it has partnerships with McKesson and receives backing from major venture investors. The platform is used worldwide by health‑economists, epidemiologists and biostatisticians for database analytics and comparative‑effectiveness research.
QurAlis Corporation
Seed Round in 2018
QurAlis Corporation is a Cambridge, Massachusetts-based clinical-stage biotechnology company developing precision therapeutics for amyotrophic lateral sclerosis and other neurodegenerative diseases. It focuses on drugs that directly target disease-causing genetic alterations using proprietary platforms and biomarkers to identify and treat patients with specific genetic mutations, aiming to halt disease progression and improve outcomes.
Senti Biosciences
Series A in 2018
Senti Biosciences is a biotechnology company focused on synthetic biology. It develops gene circuit platforms to engineer therapeutics, with a focus on improving precision and control in cancer treatments.
Obsidian Therapeutics
Series A in 2017
Founded in 2015 and based in Cambridge, Massachusetts, Obsidian Therapeutics develops next-generation controllable cell and gene therapies designed to extend adoptive immunotherapy to every cancer patient. Its innovative approach uses pharmacologic operating systems to precisely control protein activity in cells, enabling physicians to improve upon current cell therapies using simple, safe, orally-active marketed drugs.
Syapse
Series D in 2017
Syapse, Inc. is a technology company that specializes in precision medicine through its innovative software platform, which aggregates and analyzes clinical, molecular, treatment, and outcomes data. Founded in 2008 and headquartered in San Francisco, California, with an additional office in Radnor, Pennsylvania, Syapse aims to enhance healthcare by providing actionable insights that support data-driven decision-making in precision oncology. The company operates the Syapse Learning Health Network, a global network that enables health systems and life sciences collaborators to share real-world cancer data. This network empowers healthcare organizations to collaborate effectively, ensuring that oncologists and decision-makers have access to comprehensive patient insights at the point of care, ultimately driving improved outcomes for cancer patients. Syapse has established strategic partnerships, including a collaboration with Pfizer, to further its mission of delivering personalized care based on robust real-world evidence.
Fortuna Fix
Series B in 2017
Fortuna Fix Inc. is a clinical biotechnology company based in Laval, Canada, established in 2015. The company specializes in regenerative medicine, focusing on restoring full neuronal functionality to address neurodegenerative diseases and neurotrauma. Fortuna Fix utilizes a direct cell reprogramming technology platform and proprietary bio-scaffolding technology to develop innovative treatments. Its primary programs target spinal cord injury and Parkinson's disease, while the company also explores additional applications in stroke, traumatic brain injury, hearing loss, and amyotrophic lateral sclerosis (ALS). Through its ethical regenerative medicine initiatives, Fortuna Fix aims to provide effective solutions for patients suffering from these debilitating conditions.
Kymera Therapeutics
Series A in 2017
Kymera Therapeutics is a biotechnology company focused on targeted protein degradation. It employs a proprietary predictive modeling platform to discover novel small molecule therapeutics that selectively degrade disease-causing proteins.
immatics biotechnologies
Series E in 2017
immatics is a biopharmaceutical company focused on the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors.
The company's customized Adoptive Cell Therapies (ACTengine) and antibody-like TCR Bispecifics are the two main product classes in the pipeline (TCER). With a focus on particularly difficult-to-treat solid malignancies, each therapy modality has unique characteristics to create the desired therapeutic impact for patients at various disease stages and with various types of tumors.
immatics biotechnologies was established in 2000 by Hans Rammensee, Harpreet Singh, and Steffen Walter in Tübingen, Baden-Wurttemberg.
Aitia
Venture Round in 2017
Aitia is a leader in the application of Causal AI and Digital Twins focused on advancing drug discovery and development. The company utilizes machine learning and the convergence of multi-omic patient data to create Digital Twins that replicate the biological mechanisms of diseases. This innovative approach is particularly impactful in areas such as oncology, neurodegenerative disorders, and immunology. Aitia's Gemini Digital Twins are currently employed to identify novel therapies and expedite research and development in various conditions, including multiple myeloma, prostate cancer, Alzheimer’s Disease, Parkinson’s Disease, and Huntington’s Disease, with additional projects underway. The company collaborates with several prominent pharmaceutical firms, academic institutions, medical societies, and patient advocacy groups worldwide, thereby enhancing the potential for breakthroughs in medicine.
Darmiyan
Non Equity Assistance in 2017
Darmiyan develops a SaaS platform, BrainSee, for early detection and monitoring of neurodegenerative diseases like Alzheimer's. Using standard MRI scans and cognitive tests, BrainSee generates detailed brain maps and scores indicating neurodegeneration, enabling timely diagnosis and intervention.
NextCODE Health
Series B in 2017
WuXi NextCODE operates as a clinical diagnostics company specializing in sequence-based genomics. The firm provides a platform that assists physicians in obtaining critical clinical insights, enabling rapid and accurate diagnoses for patients. Its services include genome interpretation, data analysis, and data mining, along with security and data protection measures. The company also offers custom integration services and both clinical-grade and non-clinical-grade sequencing. With technology developed over 16 years at deCODE genetics, WuXi NextCODE aims to facilitate the integration of genomic data into patient care and diagnosis. Based in Cambridge, Massachusetts, the company was acquired by WuXi AppTec in 2015 and has since focused on addressing the challenges of genome interpretation and big data in healthcare.
Science 37
Series C in 2017
Science 37 specializes in decentralized clinical trials, offering a technology-driven approach that enables patients to participate from their homes. The company's platform connects researchers with patients via telemedicine investigators and mobile nurses, accelerating trial enrollment and retention while reaching a more diverse patient population.
immatics biotechnologies
Series E in 2017
immatics is a biopharmaceutical company focused on the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors.
The company's customized Adoptive Cell Therapies (ACTengine) and antibody-like TCR Bispecifics are the two main product classes in the pipeline (TCER). With a focus on particularly difficult-to-treat solid malignancies, each therapy modality has unique characteristics to create the desired therapeutic impact for patients at various disease stages and with various types of tumors.
immatics biotechnologies was established in 2000 by Hans Rammensee, Harpreet Singh, and Steffen Walter in Tübingen, Baden-Wurttemberg.
SiteOne Therapeutics
Series B in 2017
SiteOne Therapeutics is a San Francisco-based company developing innovative therapeutics and diagnostics for acute and chronic pain. Their lead candidates are selective inhibitors of the Naᵥ1.7 ion channel, aiming to treat pain safely and effectively without relying on NSAIDs or opioids.
eHealth Ventures
Corporate Round in 2016
Founded in 2014, eHealth Ventures is a venture capital firm based in Tel Aviv, Israel. It focuses on investing in early-stage digital health companies, particularly those specializing in digital therapeutics and diagnostics.
Akili Interactive
Series B in 2016
Akili Interactive Labs, Inc., established in 2011 and headquartered in Boston, Massachusetts, specializes in developing digital medicine solutions. The company's core business involves creating video game-based technology to assess and enhance cognitive abilities. Akili's broad pipeline focuses on treating cognitive deficiencies and improving symptoms associated with various medical conditions, such as ADHD, MDD, ASD, and inflammatory diseases.
Tizona Therapeutics
Series B in 2016
Founded in 2014, Tizona Therapeutics is a biopharmaceutical company based in South San Francisco, California. It specializes in developing immunotherapies for cancer and autoimmune diseases, with a focus on understanding the role of regulatory T cells in various tumors.
Unilife
Post in 2016
Unilife is a U.S.-based medical device and technology company specializing in the design, development, manufacturing, and supply of innovative delivery systems for injectable drugs and vaccines. The company has created a drug delivery platform that offers smart, reusable auto injectors, allowing patients to control the speed of injection. This technology enhances the delivery of therapies that come in standard prefilled barrels, thereby supporting pharmaceutical and biotechnology companies in providing injectable biologics, drugs, and vaccine products. Through its focus on differentiated delivery systems, Unilife aims to improve patient experiences and outcomes in drug administration.
Tizona Therapeutics
Series A in 2016
Founded in 2014, Tizona Therapeutics is a biopharmaceutical company based in South San Francisco, California. It specializes in developing immunotherapies for cancer and autoimmune diseases, with a focus on understanding the role of regulatory T cells in various tumors.
Alector
Series D in 2016
Alector, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for neurodegenerative diseases, including Alzheimer’s disease and frontotemporal dementia. Founded in 2013 and headquartered in South San Francisco, California, the company utilizes advanced antibody technology and insights from neuroimmunology and human genetics to create innovative treatments. Alector’s pipeline includes several candidates, such as AL001, which is undergoing phase II clinical trials for frontotemporal dementia, and AL101, currently in phase I trials for Alzheimer's and Parkinson's diseases. Additionally, AL002 and AL003 are in phase 1b trials for Alzheimer’s disease. The company is actively engaged in research and development, with a total of ten programs at various stages. Alector has formed a strategic collaboration with Adimab, LLC to enhance its antibody research and development capabilities, aiming to efficiently generate and validate antibody drugs that target key disease-related mechanisms.
Catherex
Acquisition in 2015
In April 2010, Medigene assigned its development program of oncolytic (cancer-killing) herpes simplex viruses (oHSV), to Catherex, Inc.
Dezima Pharma
Acquisition in 2015
Dezima Pharma B.V., founded in 2012 and located in Naarden, the Netherlands, specializes in the development of protein-based compounds aimed at treating cardiovascular diseases associated with dyslipidemia. The company focuses on creating innovative drug therapies, particularly a cholesteryl ester transfer protein inhibitor, which is designed to reduce low-density lipoprotein cholesterol levels. This pharmacological approach aims to lower the risk of cardiovascular diseases, thereby providing clinicians with effective treatment options for dyslipidemic patients.
Ra Pharmaceuticals
Series B in 2015
Ra Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing therapeutics for diseases linked to the excessive activation of the complement system. Utilizing a peptide chemistry platform, the company produces synthetic macrocyclic peptides that offer the specificity and diversity of antibodies alongside the pharmacological advantages of small molecules. Its lead product candidate, Zilucoplan, is an injectable treatment that has completed Phase II clinical trials for generalized myasthenia gravis and paroxysmal nocturnal hemoglobinuria, as well as a Phase Ib trial for patients with renal impairment. In addition to Zilucoplan, Ra Pharmaceuticals is advancing pre-clinical programs targeting Factor D inhibition for C3 glomerulonephritis and dense deposit disease, among other conditions. The company has also established a collaboration with Merck & Co., Inc. to explore orally available cyclic peptides for cardiovascular targets. Founded in 2008, Ra Pharmaceuticals operates as a subsidiary of UCB SA.
Precision BioSciences
Series A in 2015
Precision BioSciences, founded in 2006, is a biotechnology company headquartered in Durham, North Carolina. It specializes in genome editing, developing therapeutic products using its proprietary ARCUS technology. The company focuses on creating allogeneic CAR T immunotherapies to treat cancers like acute lymphoblastic leukemia and non-hodgkin lymphoma, as well as genetic disorders.
Viridian Therapeutics
Series B in 2015
Viridian Therapeutics is a biotechnology company dedicated to developing treatments for patients with underserved diseases. Its primary focus is on thyroid eye disease, a debilitating orphan condition, using product candidates such as Veligrotug.
Surface Oncology
Series A in 2015
Surface Oncology, Inc. is a clinical-stage immuno-oncology company based in Cambridge, Massachusetts, focused on developing innovative cancer therapies. The company specializes in creating human immunoglobulin isotype G4 monoclonal antibodies, including SRF231, which inhibits CD47; NZV930, which targets CD73; SRF617, which inhibits CD39; SRF388, aimed at interleukin 27; and SRF813, which targets CD112R. Additionally, Surface Oncology is advancing several preclinical programs that address other critical elements of the tumor microenvironment, such as regulatory T cells and natural killer cells. The company has established strategic collaborations with Novartis Institutes for Biomedical Research and Merck Sharp & Dohme Corp. to advance the development of its therapies, including evaluating the combination of SRF617 with Merck’s KEYTRUDA. Founded in 2014, Surface Oncology aims to leverage novel immunotherapy targets and insights into cancer immuno-biology to enhance anti-tumor immune responses.
Ziarco
Series B in 2014
Ziarco, Inc. is a biotechnology company founded in 2012 and headquartered in Palo Alto, California. The company specializes in the development of therapeutic agents aimed at treating inflammatory and allergic diseases. Its primary focus is on inflammatory skin disorders, and it has established a product pipeline that includes a histamine H4 receptor antagonist program. This program targets various therapeutic areas, such as asthma, allergic rhinitis, pruritus, and skin diseases, providing innovative treatment options for conditions like atopic dermatitis and psoriasis. Through its research and development efforts, Ziarco aims to offer effective solutions for patients suffering from these challenging health issues.
Imago BioSciences
Series A in 2014
Imago BioSciences, Inc. is a clinical-stage biotechnology company based in Redwood City, California, founded in 2012. The company specializes in developing novel small molecule therapeutics aimed at treating hematologic diseases, including myelodysplastic syndromes, acute myelogenous leukemia, and other conditions associated with bone marrow failure. Central to its research is the enzyme lysine-specific demethylase 1 (LSD1), which is involved in the regulation of blood cell production. Imago BioSciences is focused on translating advanced scientific insights into transformative therapies that can alter the course of disease, thereby enhancing the quality and longevity of life for patients. Its lead product candidate, Bomedemstat, is an orally administered LSD1 inhibitor currently under evaluation for its potential to modify disease progression in patients with myeloproliferative neoplasms, a group of chronic bone marrow cancers.
NexImmune
Venture Round in 2014
NexImmune, Inc. is a clinical-stage biopharmaceutical company based in Gaithersburg, Maryland, focused on developing innovative immuno-therapeutics utilizing its proprietary Artificial Immune (AIM) technology. Founded in 2011, the company aims to enhance the immune system's response to various diseases, including cancer, inflammation, viral infections, transplant rejection, and autoimmunity. NexImmune's lead product candidates are AIM101, an aAPC-based injectable therapy targeting specific solid tumors, and AIM ACT, an adoptive cellular therapy for hematological malignancies. The AIM technology facilitates a controllable and reproducible immune response by leveraging the body's T cells to initiate targeted actions against specific antigens, even in conditions where natural antigen presenting cells are compromised. Currently, NexImmune is advancing its therapies through clinical trials, including NEXI-001 for acute myeloid leukemia and NEXI-002 for multiple myeloma.
Viridian Therapeutics
Series B in 2014
Viridian Therapeutics is a biotechnology company dedicated to developing treatments for patients with underserved diseases. Its primary focus is on thyroid eye disease, a debilitating orphan condition, using product candidates such as Veligrotug.
Atara Biotherapeutics
Series B in 2014
Atara Biotherapeutics, Inc. is a biotechnology company focused on developing off-the-shelf T-cell immunotherapies for patients with cancer, autoimmune diseases, and viral infections. The company is advancing tabelecleucel, a T-cell immunotherapy currently in Phase III clinical trials for treating Epstein-Barr virus-associated post-transplant lymphoproliferative disorder, as well as other related hematologic and solid tumors, including nasopharyngeal carcinoma. Atara is also working on next-generation CAR T immunotherapies targeting various indications, including ATA2271 and ATA3271 for mesothelin, and ATA2431 and ATA3219 for B-cell lymphomas. Additionally, its pipeline includes ATA188 for multiple sclerosis and several other candidates for conditions such as acute myeloid leukemia and cytomegalovirus. Founded in 2012, Atara Biotherapeutics is headquartered in South San Francisco, California, and collaborates with leading academic institutions to enhance its research and development efforts.
Atara Biotherapeutics
Series B in 2013
Atara Biotherapeutics, Inc. is a biotechnology company focused on developing off-the-shelf T-cell immunotherapies for patients with cancer, autoimmune diseases, and viral infections. The company is advancing tabelecleucel, a T-cell immunotherapy currently in Phase III clinical trials for treating Epstein-Barr virus-associated post-transplant lymphoproliferative disorder, as well as other related hematologic and solid tumors, including nasopharyngeal carcinoma. Atara is also working on next-generation CAR T immunotherapies targeting various indications, including ATA2271 and ATA3271 for mesothelin, and ATA2431 and ATA3219 for B-cell lymphomas. Additionally, its pipeline includes ATA188 for multiple sclerosis and several other candidates for conditions such as acute myeloid leukemia and cytomegalovirus. Founded in 2012, Atara Biotherapeutics is headquartered in South San Francisco, California, and collaborates with leading academic institutions to enhance its research and development efforts.
Sutro Biopharma
Series D in 2013
Sutro Biopharma is a clinical-stage biopharmaceutical company focused on developing next-generation protein therapeutics for cancer and autoimmune disorders using its proprietary XpressCF platform. Its pipeline includes STRO-001 for multiple myeloma and non-Hodgkin lymphoma, and STRO-002 for ovarian and endometrial cancers.
Opsona Therapeutics
Series C in 2013
Opsona Therapeutics is a Dublin-based drug development company specializing in immunology, particularly the modulation of innate immunity pathways. Founded in 2004, the company has developed innovative therapeutic approaches aimed at treating autoimmune and inflammatory diseases, as well as cancer. By targeting the innate immune system, Opsona addresses a spectrum of significant health challenges, including transplant rejection, diabetes, Alzheimer's disease, and atherosclerosis. The company seeks to improve patient outcomes through its novel drug candidates and strategies, positioning itself as a leader in emerging immunology research and drug development in Europe.
Onyx Pharmaceuticals
Acquisition in 2013
Onyx Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for cancer treatment. The company's primary product is Nexavar, an oral multiple kinase inhibitor designed to target proteins that contribute to tumor cell proliferation and angiogenesis. By concentrating on improving the quality of life for cancer patients, Onyx Pharmaceuticals aims to deliver effective treatment options within the competitive landscape of oncology.
Opsona Therapeutics
Series C in 2013
Opsona Therapeutics is a Dublin-based drug development company specializing in immunology, particularly the modulation of innate immunity pathways. Founded in 2004, the company has developed innovative therapeutic approaches aimed at treating autoimmune and inflammatory diseases, as well as cancer. By targeting the innate immune system, Opsona addresses a spectrum of significant health challenges, including transplant rejection, diabetes, Alzheimer's disease, and atherosclerosis. The company seeks to improve patient outcomes through its novel drug candidates and strategies, positioning itself as a leader in emerging immunology research and drug development in Europe.
Theraclone Sciences
Series B in 2013
Theraclone Sciences, Inc. is a discovery-stage biotechnology company based in Seattle, Washington, focused on developing novel therapeutic antibodies for cancer and infectious diseases. The company employs its proprietary In-Situ Therapeutic Antibody Rescue technology to rapidly identify and test human antibodies with exceptional biological functions. Theraclone's pipeline includes TCN-032, a recombinant human monoclonal antibody aimed at treating patients hospitalized with severe influenza, along with several preclinical and clinical programs targeting unmet medical needs such as triple-negative breast cancer, infectious disease-associated cancers, and multidrug-resistant bacteria. Founded in 2004 and originally known as Spaltudaq Corporation until its rebranding in 2009, Theraclone leverages the natural immune responses of human subjects to discover rare monoclonal antibodies that could lead to effective therapeutic interventions.
Decode Genetics
Acquisition in 2012
DeCODE Genetics is a biopharmaceutical company based in Reykjavik, Iceland, founded in 1996. It focuses on analyzing the human genome to identify genetic variants associated with common diseases. The company utilizes population studies to uncover key genetic risk factors for various conditions, including cardiovascular disease and cancer. DeCODE Genetics develops diagnostic tests and technologies aimed at improving the treatment, diagnosis, and prevention of these diseases. By leveraging its expertise in chemistry and structural biology, the company also supports clients in the healthcare sector with DNA-based reference laboratory tests and consumer genome analysis services, which help assess individual risk for common diseases.
Gamida Cell
Series E in 2012
Gamida Cell Ltd., established in 1998 and headquartered in Jerusalem, Israel, is a clinical-stage biopharmaceutical company focused on developing advanced cell therapies to treat blood cancers and serious blood diseases. The company's lead product candidate, omidubicel, is an expanded hematopoietic stem cell therapy derived from umbilical cord blood, currently in Phase 3 studies for patients with high-risk hematologic malignancies and severe aplastic anemia. Additionally, Gamida Cell is developing GDA-201, a natural killer cell-based cancer immunotherapy, which is in Phase 1/2 trials for relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. Both candidates leverage the company's proprietary expansion platform based on nicotinamide to enhance cell properties and therapeutic potential.
Sutro Biopharma
Series C in 2012
Sutro Biopharma is a clinical-stage biopharmaceutical company focused on developing next-generation protein therapeutics for cancer and autoimmune disorders using its proprietary XpressCF platform. Its pipeline includes STRO-001 for multiple myeloma and non-Hodgkin lymphoma, and STRO-002 for ovarian and endometrial cancers.
MN Pharmaceuticals
Acquisition in 2012
MN is the leading supplier of pharmaceuticals to hospitals in Turkey and garnered sales of about $200 million last year, according to the statement. It was the first Turkish pharmaceutical company to win a license from the Food and Drug Administration to sell products in the U.S.
Viridian Therapeutics
Series B in 2012
Viridian Therapeutics is a biotechnology company dedicated to developing treatments for patients with underserved diseases. Its primary focus is on thyroid eye disease, a debilitating orphan condition, using product candidates such as Veligrotug.
KAI Pharmaceuticals
Acquisition in 2012
KAI Pharmaceuticals is a drug discovery and development company focused on creating innovative therapeutics for cardiovascular disease, kidney disease, and pain management. The company's lead product candidate, KAI-9803, is undergoing a Phase 2b clinical trial aimed at evaluating its ability to reduce myocardial injury in patients experiencing heart attacks. Additionally, KAI is advancing its second core program, KAI-4169, which targets secondary hyperparathyroidism in kidney disease patients and is anticipated to enter human clinical trials. The company is also exploring pain management through its ongoing program, KAI-1678, currently in Phase 2a testing.
Kuros Biosciences
Post in 2012
Kuros Biosciences is a Swiss biopharmaceutical company founded in 2000 as a spin‑off of ETH Zürich. It develops tissue‑repair and bone‑regeneration products built on proprietary technology platforms derived from research at ETH Zürich, the University of Zürich and CalTech. The company acquired Xpand Biotechnology in 2017 to expand its MagnetOs family of bone graft substitutes, which are approved in the EU for orthopedic, spinal and dental applications and in the United States for posterolateral spinal fusion. A putty formulation is pending regulatory submission. Neuroseal, a novel dural‑sealing biomaterial, is under CE review. Kuros also pursues a pipeline of clinical‑stage products, including KUR‑111 and KUR‑113 for fracture repair and a fibrin‑PTH combination that promotes bone formation. The company collaborates with Checkmate Pharmaceuticals on the oncology candidate CYT003 and maintains a legacy portfolio of medical‑device and pharmaceutical assets.
Micromet
Acquisition in 2012
Micromet is a biotechnology company focused on the research, development and commercialization of novel biological products for the treatment and control of cancer. Their lead product candidate, Canvaxin, is one of a new class of products being developed in the area of specific active immunotherapy, also known as therapeutic cancer vaccines.
Theraclone Sciences
Venture Round in 2011
Theraclone Sciences, Inc. is a discovery-stage biotechnology company based in Seattle, Washington, focused on developing novel therapeutic antibodies for cancer and infectious diseases. The company employs its proprietary In-Situ Therapeutic Antibody Rescue technology to rapidly identify and test human antibodies with exceptional biological functions. Theraclone's pipeline includes TCN-032, a recombinant human monoclonal antibody aimed at treating patients hospitalized with severe influenza, along with several preclinical and clinical programs targeting unmet medical needs such as triple-negative breast cancer, infectious disease-associated cancers, and multidrug-resistant bacteria. Founded in 2004 and originally known as Spaltudaq Corporation until its rebranding in 2009, Theraclone leverages the natural immune responses of human subjects to discover rare monoclonal antibodies that could lead to effective therapeutic interventions.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.